0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Articles |

Error in Figure in: Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab

Arch Neurol. 2009;66(11):1384. doi:10.1001/archneurol.2009.256.
Text Size: A A A
Published online

Extract

Error in Figure. In the Observation article titled “Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab” by del Pilar Martin et al, published in the August issue of the Archives (2009;66[8]:1016-1020), part B of the Figure on page 1018 was incorrect. The corrected figure appears here.

Figure.

Rituximab depletes B cells from peripheral blood, cerebrospinal fluid, and cerebral perivascular spaces (CPVS). At 6.5 months after the last dose of rituximab, no mature CD19+ B cells were identified by flow cytometry in peripheral blood (A) or cerebrospinal fluid (B) in a patient with gastrointestinal mantle-cell lymphoma who developed progressive multifocal leukoencephalopathy (PML) following rituximab therapy. C, A cerebral magnetic resonance image of the index patient obtained 6 months after the last rituximab dose. D and E, No CD20+ B cells or CD19+ B cells were detectable in CPVS of the index patient (indicated as PML with rituximab) (original magnification x40). In contrast, B cells were present in autopsy tissue of 1 patient with healthy brain tissue (D and F), 4 patients with a diagnosis of multiple sclerosis (MS) not treated with rituximab therapy (D and G), and 2 patients diagnosed with PML not associated with rituximab (indicated as PML) (D and H) (original magnification x40). D, The number of B cells in CPVS of patients who developed PML not associated with rituximab therapy was also significantly decreased compared with that in healthy cerebral tissue and tissue from patients with MS not treated with rituximab. VF indicates visual field; error bars, SEM. In E-H, an anti-CD19 monoclonal antibody (clone LE-CD19; Dako Corp, Glostrup, Denmark) was used to confirm the presence of B cells in CPVS. In F-H, arrows indicate B cells in CPVS.

Figures in this Article

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.

Rituximab depletes B cells from peripheral blood, cerebrospinal fluid, and cerebral perivascular spaces (CPVS). At 6.5 months after the last dose of rituximab, no mature CD19+ B cells were identified by flow cytometry in peripheral blood (A) or cerebrospinal fluid (B) in a patient with gastrointestinal mantle-cell lymphoma who developed progressive multifocal leukoencephalopathy (PML) following rituximab therapy. C, A cerebral magnetic resonance image of the index patient obtained 6 months after the last rituximab dose. D and E, No CD20+ B cells or CD19+ B cells were detectable in CPVS of the index patient (indicated as PML with rituximab) (original magnification x40). In contrast, B cells were present in autopsy tissue of 1 patient with healthy brain tissue (D and F), 4 patients with a diagnosis of multiple sclerosis (MS) not treated with rituximab therapy (D and G), and 2 patients diagnosed with PML not associated with rituximab (indicated as PML) (D and H) (original magnification x40). D, The number of B cells in CPVS of patients who developed PML not associated with rituximab therapy was also significantly decreased compared with that in healthy cerebral tissue and tissue from patients with MS not treated with rituximab. VF indicates visual field; error bars, SEM. In E-H, an anti-CD19 monoclonal antibody (clone LE-CD19; Dako Corp, Glostrup, Denmark) was used to confirm the presence of B cells in CPVS. In F-H, arrows indicate B cells in CPVS.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();